

### **Pfizer beats forecasts**

Pfizer Inc, which in May officially abandoned its bid to buy British rival AstraZeneca Plc, reported higher-than-expected second-quarter revenue, helped by growing demand for its cancer medicines. The largest US drugmaker on Tuesday said it had earned \$2.91 billion, or 45 cents per share. That compared with \$14.1 billion, or \$1.98 per share, a year earlier, when Pfizer received more than \$10 billion in proceeds from the spinoff of its animal health business into a new publicly traded company, Zoetis. REUTERS

Company